In a move that’s bound to shake things up, the CHMP has given a thumbs-up to Kayshild, a GLP-1 receptor agonist aimed at tackling non-cirrhotic MASH. Yes, you read that right. The first GLP-1 approved in Europe for this pesky liver issue. And it’s about time, considering that MASH is wreaking havoc on over 250 million people worldwide. Let’s face it, this condition is like a bad house guest—uninvited and hard to get rid of.
Kayshild, developed by Novo Nordisk A/S, received its conditional marketing authorization recommendation on January 29, 2026. That’s just five months after the FDA waved it through in the U.S. Conditional approval? It’s like saying, “We believe in you, but let’s not get ahead of ourselves.” The data isn’t complete, but the benefits seem to outweigh the risks. Sounds a bit like a gamble, doesn’t it? In trials, Kayshild demonstrated it could resolve MASH without making liver fibrosis worse, which is crucial as the MASH market is projected to grow significantly. This approval reflects a significant advancement in addressing autonomy for patients seeking effective treatments. Imagine that! People with moderate to advanced liver fibrosis could finally see some improvement. No one wants their liver to feel like a battle zone, right? Additionally, the CHMP has recommended approval for Kayshild after considering the significant number of patients affected by liver issues.
But, it’s not all sunshine and rainbows. Common side effects include nausea and diarrhea. So, if you’re planning on popping this wonder drug, you might want to keep your bathroom close.
The competition? Oh, it’s heating up. Rezdiffra got its own conditional approval in mid-2025, and Eli Lilly is hot on the heels with tirzepatide. Meanwhile, lanifibranor is still in trial limbo. Multiple GLP-1s are about to hit the MASH treatment market.
But let’s not overlook the fine print. The CHMP’s recommendation still needs the European Commission‘s seal of approval.
And who knows? This could be the start of something big, or just another flash in the pan. Only time will tell. Buckle up, folks.
